Neurogene Inc.
NASDAQ:NGNEBiotechnology
+$0.76 today
- Market cap
- $365.67M
- Beta
- 2.04
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$4.42
Volume 0.25M
Average 0.16M
NGNE Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Neurogene Inc.NASDAQ: NGNE
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 75.4% from a year ago
Cash & equivalents stood at $124.16M at the end of Q1 FY2026, up 75.4% from a year earlier and up 19.6% from the prior quarter. Over 3 fiscal years it compounded at +8.2% a year.
Context
- Cash & equivalents amounted to 47.2% of total assets at the end of Q1 FY2026, up 24.7 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +75.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 103.85M USD
- Year-over-year change
- -24.0%
- 4-year CAGR
- +10.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 103.85M | -24.0% |
| FY2024 | 2024-12-31 | 136.59M | -7.8% |
| FY2023 | 2023-12-31 | 148.21M | +80.7% |
| FY2022 | 2022-12-31 | 82.02M | +16.3% |
| FY2021 | 2021-12-31 | 70.54M | — |
Cash & Equivalents vs competitors
How NGNE compares with its peers on the latest reported figures
- NGNE's Mar 2026 cash & equivalents of $124.16M is the 2nd highest of the 8 companies compared; the peer median is $71.77M.
- Its year-over-year change of +75.4% is the 3rd highest of 8, against a peer median of +7.5%.
- Cash & equivalents amounts to 47.2% of total assets for NGNE, versus a peer median of 28.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $455.41M | +45.6% | +53.8% | 96.8% | |
| Mar 2026 | $124.16M | +75.4% | +8.2% | 47.2% | |
| Mar 2026 | $76.96M | +102.7% | -24.7% | 32.1% | |
| Mar 2026 | $72.49M | -45.7% | +4.8% | 14.1% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | $71.77M | +148.2% | -6.6% | 28.7% |
| Mar 2026 | $71.54M | +7.5% | -17.1% | 29.2% | |
| Mar 2026 | $43.31M | -42.1% | -12.9% | 19.7% | |
| Mar 2026 | $12.77M | -6.6% | -14.0% | 5.5% | |
| Peer median (excluding NGNE) | $71.77M | +7.5% | -12.9% | 28.7% | |
Competitors are the stored peer set for NGNE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 70.54M | 82.02M | 148.21M | 136.59M | 103.85M |
| Short-term Investments | 0 | 0 | 48.95M | 175.82M | 165.17M |
| Net Receivables | 790K | 0 | 600K | 648K | 0 |
| Inventory | 1.91M | 0 | 0 | 0 | 0 |
| Other Current Assets | (1.2M) | 1.62M | 1.1M | 981K | 2.76M |
| Total Current Assets | 73.96M | 84.72M | 200.35M | 315.92M | 271.77M |
| Property, Plant & Equipment (Net) | 27.53M | 24.55M | 20.95M | 18.49M | 15.46M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 128K | 0 | 0 | 0 | 0 |
| Long-term Investments | 878K | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | (1.01M) | 0 | 1.27M | 1.31M | 1.37M |
| Total Non-current Assets | 27.53M | 24.55M | 22.23M | 19.81M | 16.83M |
| Total Assets | 101.49M | 109.27M | 222.57M | 335.73M | 288.6M |
| Account Payables | 5.63M | 625K | 2.6M | 1.34M | 1.95M |
| Short-term Debt | 1.22M | 0 | 0 | 3M | 3.06M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 132K | 167K | 6.71M | 1.43M | 6.32M |
| Total Current Liabilities | 10.86M | 6.65M | 22.97M | 15.16M | 16.41M |
| Long-term Debt | 0 | 0 | 0 | 0 | 6.83M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 177.91M | 0 | 203K | 769K | 479K |
| Total Non-current Liabilities | 182.51M | 3.99M | 13.58M | 10.2M | 7.31M |
| Total Liabilities | 193.36M | 10.64M | 36.55M | 25.36M | 23.72M |
| Common Stock | 1K | 0 | 0 | 0 | 0 |
| Retained Earnings | (95.65M) | (150.84M) | (187.15M) | (262.3M) | (352.65M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (91.88M) | 98.63M | 186.02M | 310.38M | 264.89M |
| Total Debt | 6.43M | 4.69M | 16.26M | 12.43M | 9.89M |
| Net Debt | (64.11M) | (77.33M) | (131.96M) | (124.16M) | (93.95M) |
Neurogene Inc.
NASDAQ:NGNE
Intrinsic Alpha fair value
Locked
Current Price
$23.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.